4.8 Article

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19

期刊

NATURE COMMUNICATIONS
卷 12, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41467-021-25480-z

关键词

-

资金

  1. Rosalind Franklin Institute
  2. Rosalind Franklin Institute EPSRC [EP/S025243/1]
  3. Wellcome Trust [100209/Z/12/Z]
  4. EPA Cephalosporin Fund
  5. Oxford COVID-19 Research Response Fund
  6. MRC [MR/W005611/1]
  7. G2P-UK
  8. US Food and Drug Administration (USA) [75F40120C00085]
  9. Wellcome Trust [100209/Z/12/Z] Funding Source: Wellcome Trust
  10. MRC [MR/W005611/1] Funding Source: UKRI

向作者/读者索取更多资源

Nanobodies engineered as homotrimers show promising potential in neutralizing SARS-CoV-2 viral strains for COVID-19 treatment, especially when administered through respiratory routes. The study characterizes four nanobodies with high affinity for the receptor binding domain of the spike protein, demonstrating efficacy in inhibiting disease progression in animal models.
SARS-CoV-2 remains a global threat to human health particularly as escape mutants emerge. There is an unmet need for effective treatments against COVID-19 for which neutralizing single domain antibodies (nanobodies) have significant potential. Their small size and stability mean that nanobodies are compatible with respiratory administration. We report four nanobodies (C5, H3, C1, F2) engineered as homotrimers with pmolar affinity for the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Crystal structures show C5 and H3 overlap the ACE2 epitope, whilst C1 and F2 bind to a different epitope. Cryo Electron Microscopy shows C5 binding results in an all down arrangement of the Spike protein. C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa). Administration of C5-trimer via the respiratory route showed potent therapeutic efficacy in the Syrian hamster model of COVID-19 and separately, effective prophylaxis. The molecule was similarly potent by intraperitoneal injection. Neutralizing nanobodies (Nb) are of considerable interest as therapeutic agents for COVID-19 treatment. Here, the authors functionally and structurally characterize Nbs that bind with high affinity to the receptor binding domain of the SARS-CoV-2 spike protein and show that an engineered homotrimeric Nb prevents disease progression in a Syrian hamster model of COVID-19 when administered intranasally.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据